Skip to content

Clinical study on the prevention of chemotherapy induced peripheral neuropathy by pulsed magnetic therapy

Effect of concentrated preventive pulsed magnetic therapy on chemotherapy induced peripheral neuropathy:A prospective,randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128396
Enrollment
Unknown
Registered
2026-07-20
Start date
2026-07-21
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer patients who are receiving chemotherapy treatment with taxanes and platinum-based drugs

Interventions

Magnetotherapy Group:Pulsed Magnetic Therapy
Pseudo-magnetic therapy:No magnetic field output

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age:>=18 years old; 2. Diagnosis:Solid tumors including breast cancer, colorectal cancer and gastric cancer; 3. Chemotherapy regimen: The patient is scheduled to receive at least 12 weeks of treatment with any of the following agents: taxanes, oxaliplatin; 4. CIPN Baseline: No or mild neurotoxicity, FACT/GOG-Ntx neurotoxicity subscale score >=36/44; 5. ECOG:0-2; 6. Expected Survival: >=6 months; 7. Informed Consent: Voluntary Signature.

Exclusion criteria

Exclusion criteria: 1. CIPN:FACT/GOG-Ntx 8.0% or pre-existing diabetic peripheral neuropathy; 3. Alcohol abuse: average daily alcohol consumption over the past 6 months is more than 3 standard drinks; 4. Vitamin Deficiency It is well established that deficiencies in vitamin B1, B6, B12 or folate remain uncorrected. 5. Metallic Implants: Cardiac Pacemakers, Defibrillators, Aneurysm Clips, Internal Fixation Devices; 6. Pregnancy/Lactation; 7. Comprehension Impairment: Inability to complete the questionnaire.

Design outcomes

Primary

MeasureTime frame
FACT/GOG-Ntx;

Secondary

MeasureTime frame
Quality of Life (QoL);Chemotherapy Dose Maintenance Rate;

Countries

China

Contacts

Public ContactYi Ba

Peking Union Medical College Hospital

bayipumch@aliyun.com+86 10 69158750

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026